CBP501 suppresses macrophage induced cancer stem cell like features and metastases

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Macrophages are key players in cancer-related inflammation, promoting tumor growth and metastasis.
• Cytokines like IL-6 and TNF-α produced by macrophages drive processes such as epithelial-to-mesenchymal transition (EMT) and cancer stem cell (CSC) formation.
• The impact of CBP501 on tumor microenvironment cells, particularly macrophages, remained uninvestigated.

Purpose of the Study:

• To explore the anti-tumor mechanisms of CBP501 by examining its effects on macrophages.
• To determine if CBP501 can modulate macrophage-induced inflammation and cancer stem cell development.
• To investigate CBP501's potential to inhibit cancer cell metastasis.

Main Methods:

• Assessed CBP501's effect on lipopolysaccharide (LPS)-induced cytokine production (IL-6, IL-10, TNF-α) in macrophages.
• Evaluated CBP501's impact on tumor spheroid formation using conditioned medium from LPS-stimulated RAW264.7 macrophages.
• Investigated CBP501's role in suppressing ABCG2 expression (a CSC marker) by inhibiting VCAM-1 (cancer cells) and VLA-4 (macrophages) interactions.
• Observed CBP501's effect on 4T1 tumor cell metastasis in vivo.

Main Results:

• CBP501 significantly suppressed LPS-induced production of IL-6, IL-10, and TNF-α by macrophages.
• CBP501 inhibited tumor spheroid formation mediated by macrophage-conditioned medium.
• CBP501 suppressed CSC marker ABCG2 expression by disrupting macrophage-cancer cell interactions (VCAM-1/VLA-4).
• In vivo studies showed CBP501 suppressed metastasis of the 4T1 tumor cell line.

Conclusions:

• CBP501 exhibits anti-tumor potential by modulating the tumor microenvironment.
• CBP501 suppresses macrophage-driven inflammation and cytokine production.
• CBP501 inhibits cancer stem cell formation and metastasis through decreased macrophage-cancer cell interactions.